Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer

Abstract Background Biomarker assessments for nivolumab monotherapy efficacy in previously treated patients with non‐small cell lung cancer (NSCLC) remain unclear. We evaluated whether body mass index (BMI) and Glasgow prognostic score (GPS) are useful for assessing the efficacy of nivolumab alone a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hisao Imai, Erika Naito, Ou Yamaguchi, Kosuke Hashimoto, Hidetoshi Iemura, Yu Miura, Ayako Shiono, Atsuto Mouri, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wiley 2022-05-01
Saila:Thoracic Cancer
Gaiak:
body mass index
carcinoma
glasgow prognostic score
nivolumab
non‐small‐cell lung
performance status
Sarrera elektronikoa:https://doi.org/10.1111/1759-7714.14417
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak